This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1993 Feb;25(1 Pt 1):628-34.

Adverse effects of FK 506 overdosage after liver transplantation

M Alessiani¹, U Cillo, J J Fung, W Irish, K Abu-Elmagd, A Jain, S Takaya, D Van Thiel, T E Starzl

Affiliations

PMID: 7679825
PMCID: PMC2996874

Adverse effects of FK 506 overdosage after liver transplantation

M Alessiani et al. Transplant Proc. 1993 Feb.

. 1993 Feb;25(1 Pt 1):628-34.

Authors

M Alessiani¹, U Cillo, J J Fung, W Irish, K Abu-Elmagd, A Jain, S Takaya, D Van Thiel, T E Starzl

Affiliation

¹ Transplant Institute of Pittsburgh, PA 15213.

PMID: 7679825
PMCID: PMC2996874

No abstract available

PubMed Disclaimer

Figures

Fig 1 — Fig 1
Patient and graft actuarial survival curve.

Fig 2 — Fig 2
Summary of the incidence of nephropathy: a total of 54% of the patients developed nephropathy after the transplant. In 20% of cases, the nephropathy became chronic (see Fig 4).

Fig 3 — Fig 3
FK 506 trough plasma levels at peak SCr during the first 30 days post-OLTx: patients with early onset nephropathy (FK-dependent or with other concomitant nephrotoxic factors) vs patients without nephropathy. The difference is statistically significant

Fig 4 — Fig 4
Incidence of nephropathy and of dialysis requirement at 30, 180, and 360 days post-OLTx. At the latest follow-up (540 days), 20.5% of the alive patients are still nephropathic.

See this image and copyright information in PMC

Similar articles

Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R. Winkler M, et al. Transplant Proc. 1991 Dec;23(6):3153-5. Transplant Proc. 1991. PMID: 1721389 No abstract available.
Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results.
Pratschke J, Neuhaus R, Tullius SG, Jonas S, Bechstein WO, Neuhaus P. Pratschke J, et al. Transplant Proc. 1998 Jun;30(4):1419-21. doi: 10.1016/s0041-1345(98)00298-x. Transplant Proc. 1998. PMID: 9636575 No abstract available.
Long-term insulin requirement after liver transplantation with FK 506 in American veterans.
Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE. Tabasco-Minguillan J, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):677-8. Transplant Proc. 1993. PMID: 7679839 Free PMC article. No abstract available.
FK 506 versus cyclosporine.
Starzl TE. Starzl TE. Transplant Proc. 1993 Feb;25(1 Pt 1):511-2. Transplant Proc. 1993. PMID: 7679820 Free PMC article. Review. No abstract available.
Adverse effects associated with the use of FK 506.
Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, et al. Fung JJ, et al. Transplant Proc. 1991 Dec;23(6):3105-8. Transplant Proc. 1991. PMID: 1721372 Free PMC article. Review. No abstract available.

See all similar articles

Cited by

Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.
Katari SR, Magnone M, Shapiro R, Jordan M, Scantlebury V, Vivas C, Gritsch A, McCauley J, Starzl T, Demetris AJ, Randhawa PS. Katari SR, et al. Clin Transplant. 1997 Jun;11(3):237-42. Clin Transplant. 1997. PMID: 9193849 Free PMC article.
A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients.
Wu Z, Meng Q, Xia Y, Zhang F, You W. Wu Z, et al. J Biomed Res. 2013 Jul;27(4):305-9. doi: 10.7555/JBR.27.20130023. Epub 2013 Jun 13. J Biomed Res. 2013. PMID: 23885270 Free PMC article.
The role of environmental factors in insulin-dependent diabetes mellitus: an unresolved issue.
Kraine MR, Tisch RM. Kraine MR, et al. Environ Health Perspect. 1999 Oct;107 Suppl 5(Suppl 5):777-81. doi: 10.1289/ehp.99107s5777. Environ Health Perspect. 1999. PMID: 10502544 Free PMC article. Review.
Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery.
Yasutsune T, Kawakami N, Hirano K, Nishimura J, Yasui H, Kitamura K, Kanaide H. Yasutsune T, et al. Br J Pharmacol. 1999 Feb;126(3):717-29. doi: 10.1038/sj.bjp.0702339. Br J Pharmacol. 1999. PMID: 10188984 Free PMC article.
FK506 in solid organ transplantation.
Fung JJ, Starzl TE. Fung JJ, et al. Ther Drug Monit. 1995 Dec;17(6):592-5. doi: 10.1097/00007691-199512000-00008. Ther Drug Monit. 1995. PMID: 8588226 Free PMC article. Review.

See all "Cited by" articles

References

1. Harding MW, Galat A, Uehling DE, et al. Nature. 1989;341:758. - PubMed
1. Siekierka JJ, Hung SHY, Poe M, et al. Nature. 1989;341:755. - PubMed
1. Starzl TE, Fung JJ. JAMA. 1990;263:2686. - PMC - PubMed
1. Starzl TE, Fung J, Jordan M, et al. JAMA. 1990;264:63. - PMC - PubMed
1. Todo S, Fung JJ, Starzl TE, et al. Ann Surg. 1990;212:295. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information